

Practical Gynecology, 2nd Edition – Chapter 2 References

1. ****Laumann E, Paik A, Rosen RC.** Sexual dysfunction in United States: prevalence and predictors. *JAMA.* 1999;281;537–44.
2. ****Lewis RW, Fugi-Meyer KS, Bosch R, et al.** Epidemiology/risk factors of sexual dysfunction. *J Sex Med* 2004;1:35-39. *This landmark study is the most commonly cited population based study of sexual dysfunction, and examines its prevalence and psychosocial determinants.*
3. **Ende J, Rockwell S, Glasgow M.** The sexual history in general medicine practice. *Arch Intern Med.* 1984;144:558–61.
4. ****Basson R.** The female sexual response revisited. *J Soc Obstet Gynecol Can.* 2000;22:383–7.
5. **Tiefer L.** *Sex is Not a Natural Act and Other Essays.* Boulder, CO: Westview Press; 1995.
6. ****Basson R.** Women’s sexual dysfunction: revised and expanded definitions. *CMAJ.*2005;172:1327-1333.
7. ****Fisher WA, Rosen RC, Eardley I et al.** Sexual experience of female partners of men with erectile dysfunction: the female experience of men’s attitudes to life events and sexuality (FEMALES) study. *J Sex Med* 2005;2:675-684.
8. **Greendale GA, Hogan P, Shumaker S.** Sexual functioning in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. *J Womens Health.* 1996;5:445–58.
9. ****Dennerstein L, Hayes R.** Confronting the challenges: epidemiological study of female sexual dysfunction and the menopause. *J Sex Med* 2005;2(suppl 3):118-32.
10. ****Lindau ST, Schumm P, Laumann EO et al.** A study of sexuality and health among older adults in the United States. *N Engl J Med* 2007;357:762-74.
11. ****Sadovsky R, Nusbaum M.** Sexual health inquiry and support is a primary care priority. *J Sex Med* 2006;3:3-11.
12. ****Rosen R, Brown C, Heiman J et al.** The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000; 26:191-208.
13. **DeRogatis L, Clayton A, Lewis-D’Agostino D et al.**
http://www.ncbi.nlm.nih.gov/pubmed/18042215?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSumValidation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder. *J Sex Med.* 2007.Nov 27 [Epub ahead of print].

14. ****Basson R.** Sexual desire and arousal disorders in women. *N Engl J Med.* 2006;354:1497-1506. *Dr. Basson's excellent review of desire and arousal disorders presents a comprehensive appraisal of the literature and a critical assessment of the role of medications, including hormones. She suggests a conservative and psychosocially oriented behavioral approach combined with use of medical therapies for which there is strong evidence.*
15. **Diagnostic and Statistical Manual of Mental Disorders, 4th ed.** Washington, DC: American Psychiatric Association; 1994.
16. ****Basson R, Bergman J, Burnett A, et al.** Report of the International Consensus Development Conference on Female Sexual Dysfunction: Definitions and Classification. *J Urol.* 2000;163:888-93.
17. ****Shifren JL, Braunstein GD, Simon JA, et al.** Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med.* 2000;343: 682-8.
18. ****Leiblum SR, Koochaki PE, Rodenberg CA et al.** Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHes). *Menopause* 2006;13:46-56.
19. ****Sarrel PM.** Psychosexual effects of menopause: role of androgens. *Am J Obstet Gynecol.* 1999;180:S319-24.
20. ****Potter J.** A 60-year old with sexual difficulties. *JAMA.* 2007;297:62-633. *This is an excellent case discussion of a 60-year-old woman with sexual difficulties. Age-related changes and psychosocial and sexual history taking are addressed, and evidence for the therapy of sexual complaints in women is summarized.*
21. ****Shifren JL, Davis SR, Moreau et al.** Testosterone patch for the treatment of hypoactive sexual desire in naturally menopausal women: results from the INTIMATE NM1 Study. *Menopause.* 2006;13:770-779.
22. **North American Menopause Society.** The role of testosterone therapy in post-menopausal women: position statement of the North American Menopause Society. *Menopause.* 2005;12:497-511.
23. **Wierman ME, Basson R, Davis S et al.** Androgen therapy in women: an endocrine society practice guideline. *J Clin Endocrinol Metab* 2006;91:3697-3710. *The Endocrine Society Clinical Practice Guidelines carefully review the evidence for and safety issues of testosterone therapy. Despite evidence of efficacy for short term use in estrogenized androgen-deficient women, they recommend against the use of testosterone treatment until further data are available.*
24. ***Braunstein G.** Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. *J Sex Med* 2007;4:859-866. *This paper reviews the two year safety data on testosterone therapy. Low rates of hirsutism and acne are seen in treated women whose serum testosterone levels are physiologic or slightly elevated; decreases in HDL are seen with oral testosterone only.*

25. **Segreaves RT, Clayton A, Croft H et al.** Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. *J Clin Psychopharmacol.* 2004;24:339-42.
26. **Rossouw JE, Anderson GL, Prentice RL et al.** Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. *JAMA.* 2002;288:321-333.
27. **Billups KL, Berman L, Berman J, et al.** A new non-pharmaceutical vacuum therapy for female sexual dysfunction. *J Sex Marital Ther.* 2001;27:435-41.
28. **Berman JR, Berman LA, Toler SM, et al.** Safety and efficacy of sildenafil for the treatment of female arousal disorder: A double-blind, placebo controlled study. *J Urol.* 2003;170:2333-8.
29. **Caruso S, Rugolo S, Agnello C, Intelisano G, Di Mari L, Cianci A.** Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. *Fertil Steril.* 2006 May;85(5):1496-501.
30. ****Clayton A, Pradko JF, Croft HA et al.** Prevalence of sexual dysfunction among newer antidepressants. *J Clinical Psychiatry* 2002;63:357-366.
31. ****Dobkin et al.** Bupropion improves sexual functioning in depressed minority women: an open label switch study. *J Clin Psychopharmacol* 2006;26:21-6.
32. ****Clayton AH, Warnock JK, Kornstein SG et al.** A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. *J Clinical Psychiatry.* 2004;65:62-67.
33. **Nurnberg HG, Hensley PL, Lauriello J, et al.** Sildenafil for women with antidepressant-induced sexual dysfunction. *Psychiatr Serv.* 1999;50:1076-8.
34. ****Goldstein I.** Current management strategies of the postmenopausal patient with sexual health problems. *J Sex Med.* 2007;4(suppl 3):235-253. *Dr. Goldstein's review of postmenopausal sexual problem management contains several case studies integrated with a clinical management paradigm. The review is comprehensive and well-referenced, and presents a specialized and complex approach to sexual problem assessment and treatment, including controversial off-label uses of medications.*
35. ****Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM.** Hysterectomy and sexual functioning. *JAMA.* 1999;282:1934-41.
36. **Shifren JL, Avis NE.** Surgical menopause: effects on psychological well-being and sexuality. *Menopause.* 2007;14:586-91.
37. **Anderson BL, Anderson B, deProse C.** Controlled prospective longitudinal study of women with cancer: II. Sexual functioning outcomes. *J Consult Clin Psychol.* 1989;57: 692-7.

38. ****Annon JS.** Behavioral Treatment of Sexual Problems: Brief Therapy. Hagerstown, MD: Harper & Row; 1976.